1071433-05-0 Usage
Uses
Used in Pharmaceutical Industry:
1-Methylindazole-4-carboxylic acid is used as a pharmaceutical agent for its anti-inflammatory and analgesic properties, serving as a potential treatment for a range of inflammatory conditions. Its capacity to modulate inflammatory responses and alleviate pain positions it as a valuable asset in the development of new therapeutics.
Used in Drug Discovery and Development:
In the realm of drug discovery and development, 1-Methylindazole-4-carboxylic acid is utilized as a lead compound for the exploration of novel therapeutic agents. Its unique structure and functional group provide a foundation for the design and synthesis of new molecules with improved pharmacological profiles.
Used in Organic Synthesis:
1-Methylindazole-4-carboxylic acid is employed as a synthetic building block in the creation of new organic molecules and materials. Its reactivity and structural features make it a versatile component in the synthesis of complex organic compounds, contributing to advancements in material science and related fields.
Check Digit Verification of cas no
The CAS Registry Mumber 1071433-05-0 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,7,1,4,3 and 3 respectively; the second part has 2 digits, 0 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 1071433-05:
(9*1)+(8*0)+(7*7)+(6*1)+(5*4)+(4*3)+(3*3)+(2*0)+(1*5)=110
110 % 10 = 0
So 1071433-05-0 is a valid CAS Registry Number.
1071433-05-0Relevant articles and documents
ORNITHINE DERIVATIVE
-
Page/Page column 24; 38, (2010/01/29)
Provided is a compound which is useful as a therapeutic agent for chronic renal insufficiency and a therapeutic agent for diabetic nephropathy. The present inventors have made extensive studies on an ornithine derivative having an antagonistic action against an EP4 receptor, and as a result, they have found that by introducing cycloalkanediyl at a C terminal of the ornithine part of the compound of the present invention, the physicochemical properties such as solubility, and the like can be improved, thereby giving further preferred properties as a pharmaceutical. Therefore, they have completed the present invention. The compound of the present invention exhibits a good antagonistic action against an EP4 receptor, and thus, it is useful as a therapeutic agent for chronic renal insufficiency and diabetic nephropathy.